The short answer
No GLP-1 is yet FDA-approved for fatty liver disease, but semaglutide has strong MASH trial data and is prescribed off-label, often through an obesity or diabetes pathway.
GLP-1 medications specifically
Semaglutide showed MASH resolution in phase 3 (ESSENCE); FDA review is ongoing. Currently off-label/investigational for liver disease.
BMI & eligibility
Coverage runs through obesity or type 2 diabetes; fatty liver disease itself is not a covered GLP-1 indication as of 2026.
Check your BMI
BMI calculator
BMI 27-29.9 — eligible if comorbidity (T2D, hypertension, sleep apnea, PCOS).
BMI is one signal among several. Waist circumference, body composition, metabolic markers, and clinical history also matter — talk to a prescriber.
Insurance & coverage
No insurer covers a GLP-1 for fatty liver directly. Document obesity or diabetes for prior authorization. This may change if the FDA approves semaglutide for MASH.
Check if your plan covers itWe earn affiliate commissions from listed providers. See our editorial standards.
Other GLP-1s for fatty liver disease (MASH/NAFLD)
GLP-1 medications for other conditions
Sources
Educational information, not medical advice. FDA-approval status reflects labeling as of 2026; off-label prescribing is legal and common but coverage varies.